MedTrace Logo

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

NCT01790152 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 420

Last updated 2026-05-18

No results posted yet for this study

Summary

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.

Conditions

  • Hodgkin Lymphoma in Remission
  • Leukemia in Remission
  • Lymphoblastic Lymphoma
  • Osteosarcoma
  • Recurrent Leukemia
  • Recurrent Lymphoma
  • Recurrent Malignant Neoplasm

Interventions

OTHER

Assessment of Therapy Complications

Ancillary studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

  • Children's Oncology Group

    lead NETWORK

  • National Cancer Institute (NCI)

    collaborator NIH

Principal Investigators

  • Eric J Chow · Children's Oncology Group

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-05
Primary Completion
2022-12-31
Completion
2026-12-31

Countries

  • United States
  • Australia
  • Canada
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01790152 on ClinicalTrials.gov